Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Anlotinib in Recurrent/Metastatic HNSCC After Platinum Failure
ChiCTR2100044229Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Objective response rate (ORR) and Disease control rate (DCR). Started Mar 2021; status: recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100044229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044229.